Treatment alternatives in massive hemorrhage;Alternativas terapéuticas de la hemorragia masiva

Medicina Intensiva

Volumn 36, Issue 7, 2012, Pages 496-503

  Fernandez Hinojosa E ^a   Murillo Cabezas, F ^a   Puppo Moreno, A ^a   Leal Noval, S R ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Erythrocytes; Fibrinogen; Massive hemorrhage; Plasma; Platelets; Point care; Prothrombin concentrate complex; Thromboelastography; Tranexamic; Transfusion

Indexed keywords

FIBRINOGEN; HEMOSTATIC AGENT; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7; TRANEXAMIC ACID; UNCLASSIFIED DRUG;

BLEEDING; BLOOD CLOTTING DISORDER; COST BENEFIT ANALYSIS; CRYSTALLOID; ERYTHROCYTE TRANSFUSION; MASSIVE BLEEDING; PLASMA TRANSFUSION; POINT OF CARE TESTING; SHORT SURVEY; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE TRANSFUSION; THROMBOELASTOGRAPHY;

BLOOD TRANSFUSION; HEMORRHAGE; HUMANS; SEVERITY OF ILLNESS INDEX;

EID: 84865997860     PISSN: 02105691     EISSN: 15786749     Source Type: Journal    
DOI: 10.1016/j.medin.2011.11.010     Document Type: Short Survey

References (48)

1. Karkouti K., Wijeysundera D.N., Yau T.M., Beattie W.S., Abdelnaem E., McCluskey S.A., et al. The independent association of massive blood loss with mortality in cardiac surgery. Transfusion 2004, 44:1453-1462.
2. Leal-Noval S.R., Jiménez-Sánchez M. La transfusión de hematíes incrementa la oxigenación tisular y mejora el resultado clínico (con). Med Intensiva 2010, 34:471-475.
3. Spanh DR, Cerny V, Coast TJ, Duranteau J, Fernández-Modéjar E, Gordini G et al. Management of bleeding following major trauma: a European guideline. Crit Care 2007; 11:R17 (doi:10.1186/cc5686).
4. Bolliger D., Szlam F., Levy J.H., Molinaro R.J., Tanaka K.A. Haemodilution induced profibrinolytic state is mitigated by fresh-frozen plasma: Implications for early haemostatic intervention in massive haemorrhage. Br J Anaesth 2010, 104:318-325.
5. Santry Heena P., Alam Hasan B. Fluid resuscitation: past, present, and the future. Shock 2010, 33:229-241.
6. Mittermayr M., Streif W., Haas T., Fries D., Velik-Salchner C., Klingler A., et al. Effects of colloid and crystalloid solutions on endogenous activation of fibrinolysis and resistance of polymerized fibrin to recombinant tissue plasminogen activator added ex vivo. Br J Anaesth 2008, 100:307-314.
7. Fries D., Innerhofer P., Klingler A., Berresheim U., Mittermayr M., Calatzis A., et al. The effect of the combined administration of colloids and lactated Ringer's solution on the coagulation system: An in vitro study using thrombelastograph coagulation analysis (ROTEM). Anesth Analg 2002, 94:1280-1287.
8. Stern S.A. Low-volume fluid resuscitation for presumed hemorrhagic shock: helpful or harmful?. Curr Opin Crit Care 2001, 7:422-430.
9. Theusinger O.M., Spahn D., Ganter M.T. Transfusion in Trauma: why and how should we change our current practice?. Curr Opin Anaesthesiol 2009, 22:305-312.
10. Cotton B.A., Dosset L.A., Haut E.R., Shafi S., Núñez T.C., Au B.K., et al. Multicenter validation of a simplified score to predict massive transfusion in trauma. J Trauma 2010, 69(suppl 1):S33-S39.
11. Dente C.J., Shaz B.H., Nicholas J.M., Harris R.S., Wyrzykowski A.D., Patel S., et al. Improvements in early mortality and coagulopathy are sustained better in patients with blunt trauma after institution of a massive transfusion protocol in a civilian level I trauma center. J Trauma 2009, 66:1616-1624.
12. Holcomb J.B., Hess J.R. Early massive trauma transfusion: State of the Art. J Trauma 2006, 60:S1-S2.
13. Borgman M.A., Spinella P.C., Perkins J.G., Grathwohl K.W., Repine T., Beekley A.C., et al. The ratio of blood products transfused affects mortality in patients receiving massive transfusions at a combat support hospital. J Trauma 2007, 63:805-813.
14. Johansson P.I., Stensballe J. Hemostatic resuscitation for massive bleeding: the paradigm of plasma and platelets-a review of the current literature. Transfusion 2010, 50:701-710.
15. Dirks J., Jorgensen H., Jensen C.H., Ostrowsky S.R., Johansson P.I. Blood product ratio in acute traumatic coagulopathy-effect on mortality in a Scandinavian level 1 trauma centre. Scand J Trauma Resusc Emerg Med 2010, 18:65.
16. th Edition). Chest 2008, 133:160S-198S.
17. Romans R. Issues of AB plasma by Month for the last 4 Years in Canada 2009, Canadian Blood Service, Ottawa, Ontario, Canada.
18. Rossaint R., Bouillon B., Cerny V., Coats T.J., Duranteau J., Fdez-Mondejar E., et al. Management of bleeding following mayor trauma: An update European guideline. Crit Care 2010, 14:R52.
19. Roback J.D., Caldwell S., Carson J., Davenport R., Drew M., Eder A., et al. A Evidence based practice guidelines for plasma transfusion American Association for the Study of Liver; American Academy of Pediatrics; US Army; American Society of Anesthesiology; American Society of Hematology. Transfusion 2010, 50:1227-1239.
20. Rajasekhar A., Gowing R., Zarychanski R., Arnold D.M., Lim W., Crowther M.A., et al. Survival of trauma patients after massive red blood cell transfusion using a high or low red blood cell to plasma transfusion ratio. Crit Care Med 2011, 39:1507-1513.
21. Shaz B.H., Dente C.J., Harris R.S., MacLeod J.B., Hillyer C.D. Transfusion management of trauma patients. Anesth Analg 2009, 108:1760-1768.
22. Theusinger O.M., Spahn D., Ganter M.T. Transfusion in trauma: why and how should we change our current practice?. Curr Opin Anaesthesiol 2009, 22:305-312.
23. Fraga G.P., Bansal V., Coimbra R. Transfusión of blood products in trauma: an update. J Emerg Med 2010, 39:253-260.
24. Greuters S., van den Berg A., Franschman G., Viersen V.A., Beishuizen A., Peerdeman S.M., et al. Acute and delayed mild coagulopathy are related to outcome in patients with isolated traumatic brain injury. Crit Care 2011, 15:R2. ALARM-BLEEDING investigators.
25. Schochl H., Nienaber U., Hofer G., Voelckel W., Jambor C., Scharbert G., et al. Goal-directed coagulation management of major trauma patients using thromboelastometry (ROTEM)-guided administration of fibrinogen concentrate and protrombin complex concentrate. Crit Care 2010, 14:R55.
26. Bolliger D., Görlinger K., Tanaka K.A. Pathophysiology and treatment of coagulopathy in massive hemorrhage and hemodilution. Anesthesiology 2010, 113:1205-1219.
27. Geeraedts L.M.G., Kaasjager H.A.H., Van Vugt A.B., Frölke J.P.M. Exanguination in trauma: A review of diagnostics and treatment options. Injury 2009, 40:11-20.
28. Schochl H., Frietsch T., Pavelka M., Jambor C. Hyperfibrinolysis after major trauma: Differential diagnosis of lysis patterns and prognostic value of thrombelastometry. J Trauma 2009, 67:125-131.
29. Bolliger D., Szlam F., Molinaro R.J., Rahe-Meyer N., Levy J.H., Tanaka K.A. Finding the optimal concentration range for fibrinogen replacement after severe haemodilution: An in vitro model. Br J Anaesth 2009, 102:793-930.
30. Shore-Lesserson L., Manspeizer H.E., Francis S., DePerio M. Intraoperative [Thrombelastograph® Analysis] (TEG [®]) Reduces Transfusion Requirements. Anesth Analg 1998, 86:SCA101.
31. Rugeri L., Levrat A., David J.S., Delecroix E., Floccard B., Gros A., et al. Diagnosis of early coagulation abnormalities in trauma patients by rotation thrombelastography. J Thromb Haemost 2007, 5:289-295.
32. Henry D.A., Carless P.A., Moxey A.J. Anti-fi brinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2007, 4:CD001886.
33. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010, 376:23-32. CRASH -2 Trial.
34. Muñoz-Sánchez A., Murillo-Cabezas F. El ácido tranexámico disminuye la mortalidad del shock hemorrágico traumático. Punto de vista. Med Intensiva 2011, 35:286-287.
35. Roberts I, Shakur H, Ker K, Coats T. On behalf of the CRASH-2 Trial collaborators. Antifibrinolytic drugs for acute traumatic injury (Review). The Cochrane library 2011.
36. Johansson P.I. Off-label use of recombinant factor VIIa for treatment of haemorrhage: results from randomized clinical trials. Vox Sang 2008, 95:1-7.
37. Boffard K.D., Riou B., Warren B., Choong P.I., Rizoli S., Rossaint R. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: Two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma 2005, 59:8-15.
38. Levy M., Levy J., Andersen H., Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 2010, 363:1791-1800.
39. O'Connell K.A. Tromboembolic Adverse Events After Use of r Factor VII a. JAMA 2006, 295:293-298.
40. Zangrillo A., Mizzi A., Boundi-Zoccai G., Bignami E., Calabrò M.G., Pappalardo F., et al. Recombinant activated factor VII in cardiac surgery: a meta-analysis. J Cardiothorac Vasc Anesth 2009, 23:34-40.
41. Gill R., Herbertson M., Vuylsteke A., Olsen P.S., von Heymann C., Mythen M., et al. Safety an efficacy of recombinant activated factor VII: a randomized placebo-controlled trial in the setting of bleeding after cardiac surgery. Circulation 2009, 120:21-27.
42. Stinger H.K., Spinella P.C., Perkins J.G., Grathwohl K.W., Salinas J., Martini W.Z., et al. The ratio of fibrinogen to red cells transfused affects survival in casualties receiving massive transfusions at an army combat support hospital. J Trauma 2008, 64:S79-S85.
43. Rahe-Meyer N., Pichlmaier M., Haverich A., Solomon C., Winterhalter M., Piepenbrock S., et al. Bleeding management with fibrinogen concentrate targeting a high-normal plasma fibrinogen level: A pilot study. Br J Anaesth 2009, 102:785-792.
44. Karlsson M., Ternstrom L., Hyllner M., Baghaei F., Flinck A., Skrtic S., et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery. A prospective randomised pilot study. Thromb Haemost 2009, 102:137-144.
45. Fenger-Eriksen C., Jensen T.M., Kristensen B.S., Jensen K.M., Tønnesen E., Ingerslev J., et al. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: A randomized, placebo-controlled clinical trial. J Thromb Haemost 2009, 7:795-802.
46. Schick K.S., Fertmann J.M., Jauch K.W., Hoffmann J.N. Prothrombin complex concentrate in surgical patients: retrospective evaluation of vitamin k reversal and treatment of severe bleeding. Crit Care 2009, 13:R191.
47. Lorenz R., Kienast J., Otto U., Egger K., Kiehl M., Schreiter D., et al. Efficacy and safety of a prothrombin complex concentrate with two virus-inactivation steps in patients with severe liver damage. Eur J Gastroenterol Hepatol 2003, 15:15-20.
48. Dickneite G., Dörr B., Kaspereit F., Tanaka K.A. Prothrombin complex concentrate versus recombinant factor VIIa for reversal of hemodilutional coagulopathy in a porcine trauma model. J Trauma 2010, 68:1151-1157.